252 related articles for article (PubMed ID: 23573612)
1. [DCIS and HER2/neu].
Tulusan AH
Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
[No Abstract] [Full Text] [Related]
2. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
Eidtmann H
Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
[No Abstract] [Full Text] [Related]
3. Advances in breast conservation therapy.
Newman LA; Kuerer HM
J Clin Oncol; 2005 Mar; 23(8):1685-97. PubMed ID: 15755977
[No Abstract] [Full Text] [Related]
4. [Radiotherapy of breast carcinoma. 2005 version].
Organgruppe "Mammakarzinom" der DEGRO
Strahlenther Onkol; 2006 Feb; 182 Suppl 1():4-28. PubMed ID: 16613299
[No Abstract] [Full Text] [Related]
5. Can some DCIS patients avoid adjuvant therapy? Still unknown.
Schmidt C
J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
7. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
Gonzalez RJ; Buzdar AU; Fraser Symmans W; Yen TW; Broglio KR; Lucci A; Esteva FJ; Yin G; Kuerer HM
Breast J; 2007; 13(1):72-5. PubMed ID: 17214797
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab not for ductal carcinoma in situ?
Nahleh Z; Namakydoust A; Bakkar R; Bishop J
Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
[TBL] [Abstract][Full Text] [Related]
9. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
Hayes DF
J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
[No Abstract] [Full Text] [Related]
10. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
11. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma-in-situ.
Wickerham DL
J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
[No Abstract] [Full Text] [Related]
13. [Therapy decision - patient participation?]].
Hilfrich J; Jänicke F
Onkologie; 2002 Dec; 25 Suppl 5():25-7. PubMed ID: 23573618
[No Abstract] [Full Text] [Related]
14. Current concepts in the treatment of early stage breast cancer.
Puckett C
Del Med J; 1992 May; 64(5):313-9. PubMed ID: 1319354
[No Abstract] [Full Text] [Related]
15. [Does molecular biology play any role in ductal carcinoma in situ?].
Sakr RA
Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
17. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
19. [Therapy concept: herceptin in combination with arimidex].
von Minckwitz G
Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
[No Abstract] [Full Text] [Related]
20. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
